Gaetano Santulli's team surveys approved oral options and late-stage pill candidates, arguing they could reach patients who avoid injections.
Recap by typeshit. Full story at BIOENGINEER.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
After 12 months, GLP-1 users shed 14.8% of the weight they had regained versus 8.1% for nonusers. Researchers stress the study was observational and small.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
Pratt's rat research suggests GLP-1 signaling can blunt reward-driven eating. He says evidence doesn't yet support GLP-1s as a binge eating disorder treatment.
A short investor post points to high cardiovascular risk among the diabetics studied and calls retatrutide's heart risk uncertain. The full take is cut off.
BiopharmIQ also notes TRIUMPH-5, which pits retatrutide directly against tirzepatide, is still running. That sets the timeline for a possible approval filing.
Loading…